PTEN activation may contribute to exquisite antitumor response to trastuzumab.
Altundag
Kadri
K
Altundag
Ozden
O
Morandi
Paolo
P
Gunduz
Mehmet
M
D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D020929:Mitogen-Activated Protein Kinase Kinases / Q000494:pharmacology; D009362:Neoplasm Metastasis; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000096:biosynthesis* / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000502:physiology; D015398:Signal Transduction; D000068878:Trastuzumab; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis* / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D020929:Mitogen-Activated Protein Kinase Kinases; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D010744:Phosphoric Monoester Hydrolases; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D025521:Tumor Suppressor Proteins; C494929:PTEN protein, human